KLOW Dosage Guide 2026: What Is Actually In the Vial

What is KLOW?

A brand name sitting over a mixture: KLOW is a vendor label for a pre-mixed vial of four separate peptides, sold for research use. It is a mixture with a name, not a compound.

What the 80 means: the vial is written as KLOW-80, KLOW 80, KLOW 80mg or klow80, and in every case the number is the total dry milligrams of all four peptides in the vial before any water goes near it. It is not a dose, not a strength per mL, and not a per-component amount. On the common label those 80mg break down as GHK-Cu 50mg, KPV 10mg, BPC-157 10mg and TB-500 10mg.

The spellings, all of them one vial: the same product is written klow, klow 80, klow-80, klow 80mg, klow 80 mg, klow80, peptide klow, klow.peptide and klow.blend. None of those variants names a different vial, a different strength or a different ratio: the punctuation is noise, the word peptide is noise, and the 80 is the label total every one of them shares.

Why "compound" is the wrong word: a compound has one sequence, one molecular formula, one mass and one registry number. A blend has four of each. KLOW has no CAS number of its own, no molecular weight of its own, and no PubChem entry of its own, because there is nothing there to register.

How easily that gets lost: a blend has no identifiers of its own, but each of its components does, and the two get run together. KPV is registered as PubChem CID 125672, Msh (11-13), with molecular formula C16H30N4O4, molecular weight 342.43 and CAS 67727-97-3. Those identifiers belong to one of the four peptides in the vial and to 10 of the 80 milligrams. Printed as though they described KLOW, they would be describing an eighth of it.

KLOW-80 is not GLOW-70: the two are one letter apart and share three of their four components, which makes them easy to mix up. GLOW is the same vial without KPV, 70mg instead of 80mg. The K in KLOW is the KPV.

What KLOW peptides are used for: the claims made for the blend, and what has actually been measured against each of them, are set out in claimed benefits versus measured evidence below.

Why there is no KLOW dosage chart on this page

What you came here for, and why it is not here: dosing charts for the 80mg vial do exist. Every one we have been able to find is published by a seller of the blend. This site names its sources or drops the claim, and it does not name sellers, so those figures are not on this page and we are not going to paraphrase them into a chart of our own.

The alternative would be worse: printing a water volume or a per-injection amount and attributing it to "a published chart" would read as sourced while pointing at nothing a reader could open. An unnamed source is not a weaker citation, it is the absence of one, and it is the failure this library exists to avoid.

What that costs, stated plainly: this page cannot tell you what volume of water anyone puts in the vial, what any chart calls a dose, how often any of them schedules an injection, or how many weeks any of them runs for. Those questions have answers circulating on the internet. We cannot show you where any of them came from, so we do not repeat them.

What does not change: the arithmetic. Whatever goes into the vial, the concentration is the label total divided by the water, and the unit reading follows from the concentration and the syringe scale. That is worked through below on example volumes of our own, none of which is a recommendation.

What would sit behind any frequency anyone prints: nothing measured. A 2026 narrative review of injectable peptide therapy in the American Journal of Sports Medicine, covering BPC-157, TB-500 and GHK-Cu among others, concludes that the indications, dosing, frequency and duration of treatment for these peptides all remain unknown (Mayfield et al., 2026). That review is about the components taken one at a time. For the four-peptide blend there is not even that.

We are not going to tell you which number is right for you, and no page that has never been asked to show its work is in a position to either.

The question no chart can answer anyway: whether a four-peptide mixture nobody has studied, at a ratio nobody enforces, does anything the four components would not do separately. That is an empirical question, it has never been put to a trial of the blend, and printing a schedule more confidently does not answer it. Our general write-up of how one vial produces two incompatible charts is in why two dose charts disagree.

The KLOW dosage calculator

Whole-blend arithmetic, not per component: it takes a vial size, a water amount, a syringe type and a dose in milligrams, and returns the concentration, the volume, and the unit reading for all four peptides together.

KLOW reconstitution: the 80mg vial at each water volume

One number on the powder side: the label total is 80mg, so the powder is settled and the whole question is the volume of water that joins it. The table below is arithmetic on example inputs of ours. It is not a recommendation, it is not carried over from anyone's protocol, and no row on it says that any particular volume is the right one.

The one line worth taking from that table: the vial does not have a concentration until someone decides the water. Everything downstream, every unit count, every chart and every calculator output, is a consequence of a choice nobody records on the glass.

What is known about keeping it once it is in solution: nothing we can cite. Searching PubMed, Europe PMC and ClinicalTrials.gov on 29 July 2026 we found no published stability study of a reconstituted four-peptide mixture. Storage windows for this blend do circulate, and their only source is a seller, so this page prints none of them. We have written separately on what is and is not known about storage after reconstitution.

How does the units math work?

What 80mg on a label buys you: nothing, until someone decides the water. The volumes worked below are examples of ours, and every figure that follows is general arithmetic with no amount attached to anyone.

An 80mg vial at two milliliters, worked out: an 80mg KLOW vial holding 2mL of bacteriostatic water sits at 40mg per mL, or 40,000mcg per mL.

Four tenths of a milligram to a unit: the U-100 barrel puts 100 units in a milliliter, so at that concentration one unit carries 0.4mg of blend.

The same vial at three and at four milliliters: 3mL leaves it at 26.7mg per mL, with a unit carrying 0.267mg rather than 0.4mg. 4mL leaves it at 20mg per mL, with a unit carrying 0.2mg, half of what the same unit carried at 2mL.

Which is the whole point: the unit reading did not change and what it carries halved. Two people converting the same unit count off the same 80mg vial can be handling masses a factor of two apart, and nothing about the syringe records which of the two they are holding.

Then the scale itself, which the water argument never touched: a unit is 0.01mL on one of the two printed scales and 0.025mL on the other, a third unstated input sitting behind the two this section has already named. The two scales are worked through in full on their own page.

The blend wrinkle: at the 50/10/10/10 label split, 62.5% of whatever mass a draw carries is GHK-Cu and 12.5% is each of KPV, BPC-157 and TB-500, whatever the size of the draw. The units math converts the blend total; the ratio inside it was fixed before the vial was sealed.

So a blend leaves four things off the barrel, not two: the water volume that set the concentration, the scale the barrel was printed to, the blend total claimed on the label, and the split inside that total. The syringe never lies about volume. It simply has no access to any of the four.

What is a KLOW protocol, and how long is a cycle?

Two meanings of one word: in a trial, a protocol is a document written before anyone is dosed, and the study is run to it and reported against it. Applied to this blend the word means a schedule somebody typed out, an amount, a frequency and a run of weeks, with no study behind it and nothing reported against it.

Why this page prints neither a schedule nor a cycle length: the schedules that circulate for this vial are published by sellers of it, and we do not name sellers, so we cannot show you where any of those weeks came from. A cycle length we cannot source is a number carrying an authority it never earned, and repeating one would be worse than leaving the question open.

Where any of those weeks would have come from: nothing measured. The same 2026 narrative review quoted above puts duration of treatment on its list of unknowns for these peptides (Mayfield et al., 2026), and that verdict is about the components taken one at a time. The blend has no trial, so it has no duration to be unknown about.

What can still be said, and only in the abstract: a weekly total is a per-injection amount multiplied by a frequency, and the number of weeks one 80mg vial covers is 80 divided by that weekly total. Both inputs have to come from somewhere. On this blend there is nowhere to get them that we could put in front of you, so the arithmetic stays a shape with no numbers in it.

The honest answer to "how long is a KLOW cycle": nobody knows, because nobody has run the study. A run of weeks is not a finding until something was measured at the end of it, and for this blend nothing has been.

Do the KLOW charts change for women, for beginners, or for bodyweight?

The direct answer: no, and there is nothing here that could. No table on this page carries a column for sex, bodyweight, age or experience, because there is no evidence base to build one from and no source we could put behind it.

Why there is nothing to condition on: a per-population number needs a population that was measured. FDA reports no human exposure data at all for TB-500 or KPV, and for BPC-157 a short list of small studies by routes other than the one this blend is sold for (FDA, PCAC July 2026), with limited human data for injectable GHK-Cu (FDA, Category 2 nominated but withdrawn list).

What a beginner chart would be: the same numbers wearing a softer label. A row that reads lower is still a row somebody picked, and calling it a starting point does not attach evidence to it that the row above it does not have.

So there is no Decadewise number here, for anyone: not for a woman, not for a first vial, not for a heavier or lighter body. The converter above changes the units on a figure you already have; where that figure came from is the question this whole page exists to ask.

Why KLOW is a blend and not a stack

The distinction people are actually searching for: "klow stack" and "klow blend peptide" return the same product, but the two words describe opposite things. A stack is several vials drawn separately, where the ratio between them is decided at every injection. A blend is one vial where the ratio was decided at the factory and cannot be changed afterwards. KLOW is the second kind. It is often written klow.blend for exactly that reason.

What the ratio actually is: on the 50/10/10/10 label the 80mg vial is 62.5% GHK-Cu and 12.5% each of KPV, BPC-157 and TB-500. Those percentages travel with every draw, whatever its size, so half a draw is half of each of the four and twice a draw is twice each of them.

The consequence, which is arithmetic rather than opinion: there is no draw from a KLOW vial that moves one component without moving all four in lockstep. Cutting the copper peptide in half cuts the KPV, the BPC-157 and the TB-500 in half at the same time. Four separate vials can be adjusted one at a time; a blend cannot, by construction. The general version of this problem lives in our note on doing the math on blend vials.

KLOW against GLOW, on the labels alone: the two names are one letter apart and the vials share three components. GLOW is labeled 70mg, as GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg. KLOW is labeled 80mg, the same three plus KPV 10mg. The K is the KPV, so the extra letter is an extra peptide rather than a different strength of the same thing, and our GLOW page takes that vial apart the same way.

What the label is, and what this page cannot tell you about the glass

The 50/10/10/10 split is a label claim: it is what the vial is sold as. It is not a standard, nothing enforces it, and there is no monograph, no compendial specification and no regulator that has ever defined what a KLOW vial must contain. Every percentage in this section is arithmetic on that claim rather than on a measurement.

Certificates of analysis for this vial exist, and this page cites none of them: every one we have found is published by a seller of the blend, on that seller's own site, and putting one in front of a reader means naming and linking that seller. We do not, so we cannot show you a certificate, and a document a reader cannot open is not a document this page will quote figures out of. What survives is the shape of the problem rather than any number from it.

Five things taken on trust, one more than a single-peptide vial: identity, ratio, purity, sterility, and the real labeled milligrams. A blend can be wrong about its milligrams and wrong about its ratio, independently of each other, and every unit count on this page assumes both are right. Nothing we can show you tests that assumption. The nearest thing to a measurement of this market that we can cite is in what is not known yet below, and it is about the supply rather than about any vial.

KLOW peptide benefits: what is claimed, and what has been measured

Why this section is a table and not a list of benefits: a benefits list would only tell you what the vendors say. The interesting column is the second one, which asks what the claim is actually resting on, and the third, which asks what anyone has measured in a human being.

The regulator's version of the same question: when the FDA reviewed three of these four for the 503A compounding list in July 2026, it recorded the use each was nominated for. BPC-157 was evaluated for ulcerative colitis. KPV was evaluated for wound healing and inflammatory conditions such as psoriasis and eczema. TB-500 was evaluated for wound healing, with the nominator not specifying what kind of wound. On each one the agency's conclusion was that there was a lack of evidence to evaluate effectiveness for the nominated use, and it proposed that none of the three be added to the list.

What that does and does not mean: "not enough evidence" is not the same as "does not work". It means nobody has run the study. Those are different sentences and only one of them is being sold to you.

KLOW before and after, and how long it takes to work

The direct answer: there is no onset figure for KLOW because no trial of the blend has ever measured a time course, and there is no before-and-after in the evidence sense because a before-and-after needs a comparator. Photographs and week-by-week write-ups have no control group, no blinding, and no record of what was actually in the vial.

Why that matters more here than usual: a 2026 review of peptide use in sports medicine covering BPC-157, TB-500 and GHK-Cu among others notes that many of these compounds show favorable repair outcomes in animal models while rigorous human safety data stay scarce, and it treats the placebo effect as an active mediator of the results people report, amplified by social media (Mendias and Awan, 2026). An uncontrolled recovery story is exactly the shape of evidence that finding predicts.

Side effects: there is no trial safety profile for this blend, so there is no side effect table on this page. What sits in the regulator's own adverse event file is in the safety picture below, and it is three voluntary reports about one component rather than a profile of anything.

What's not known yet?

Why an approval is not even possible here: KLOW is not FDA approved, neither is any component in it for general use, and the blend could not be. There is no single manufacturer, no fixed ratio, and no trial to file.

The regulator's file: all four components appear on the FDA's "nominated but withdrawn" list, pulled from the Category 2 significant-safety-risk list by their nominators, re-checked 28 July 2026 against a page the FDA dates 22 April 2026. That file says the agency has identified no human exposure data at all for TB-500 and KPV, cites limited human data for injectable GHK-Cu, and reports no, or only limited, safety information for BPC-157.

What happened on 23 July 2026: BPC-157, KPV and TB-500 went before the FDA's Pharmacy Compounding Advisory Committee, considered for the 503A Bulks List. The nominations had been withdrawn by their nominators, two compounding businesses, and the agency chose to present them anyway. In its briefing document the FDA proposed that none of the three, in free base or acetate form, be added to the list, on the grounds that they are poorly characterized chemically, that the extent of their use in compounding is unknown, and that there is not enough information about their use in humans to reach a conclusion on safety or effectiveness.

The committee disagreed with its own agency's scientists: the question put to it, printed in FDA's meeting materials, was whether each substance should be placed on the 503A list, free base and acetate voted separately. It voted yes on all three. The Associated Press and NBC News, both reporting from the meeting on 23 July 2026, put the tally at 8 in favor, 6 against and 1 abstention, and NBC records that all eight yes votes came from members newly appointed to the committee. A recommendation is advisory and does not bind the agency, which decides by rulemaking. As of 29 July 2026 the FDA meeting page publishes an agenda, briefing documents and slides, with no minutes, no vote record and no decision.

The blend-shaped holes:

• No published study of the blend itself, at any dose. PubMed returns zero results, checked 28 July 2026.
• No registered trial of the blend either. ClinicalTrials.gov returns zero, checked 28 July 2026.
• No verified data on how the four components interact when combined.
• No fixed ratio: the 50/10/10/10 split is a label claim rather than a standard, and nothing enforces it.

A blend does not inherit evidence from its parts, and there is no evidence for this blend.

What would change our read: a controlled human trial of the blend, which does not exist and is not registered. Two of the four components already carry small controlled human studies, and both of those are topical. A randomized study of a GHK-Cu skin care regimen after carbon dioxide laser resurfacing, 13 completers, found no difference between groups on the blinded objective measures and a significant difference on the patients' own rating of overall skin quality, P equal to .04 (Miller, 2006). A double-blind, placebo-controlled, dose-escalation phase 2 of topical thymosin beta-4 in 73 randomized patients with venous ulcers found the safety profile comparable to placebo, and its authors report that the 0.03% dose may have the potential to accelerate healing (Guarnera, 2010). Neither tested an injection, neither tested KPV, and neither tested the mixture. The claim that survives all of that is the narrow one, about the blend itself.

What the supply looks like, from the one source here that measured any of it: a 2026 analysis of 6,441 samples covering fourteen compounds, including BPC-157, TB-500 and GHK-Cu, found 41.6 to 71.1 percent failing basic quality criteria depending on the standard applied, with measurable endotoxin in 15 percent (Mendias and Awan, 2026, preprint, not peer reviewed). That is a statement about the market these vials come out of. It is not a measurement of any particular vial, and it is as close to the question of what is in the glass as this page can honestly get.

How this page is sourced

Nothing here is second-hand: the research figures came off the cited abstracts and the regulatory claims off the FDA's own pages and meeting documents, never off anyone's summary of either.

The thirteen sources: six primary papers, two 2026 reviews, one 2026 preprint, two regulator records, one chemical database entry, and one entry for the news reporting of the committee vote, with DOIs, PubMed IDs and links. Each is listed below with its identifier, and every figure on this page traces back to one of them.

What changed on 2 August 2026, and what it cost: until today this page compared what two published dosing charts state for the same vial, and quoted six certificates of analysis for an 80mg vial. All eight of those documents are published by sellers of the blend. Under the rule this site now works to, a source we cannot name is a source we cannot cite, and a claim we cannot cite is cut rather than softened. So the chart comparison went, and with it every water volume attributed to anyone, every per-injection amount, every weekly total, every cycle length, the storage window, and every assay figure, together with the eight reference entries that carried them.

Two of those entries were added earlier the same day, to fix the opposite problem: thirty-two attributions to two named pages had been sitting above a reference list that held neither of them. Adding the entries was right under the rule as it then stood and is wrong under this one. Citing a source properly and not naming it at all cannot both be satisfied, and when they collide the claim goes rather than the rule.

One registry record went the same day, for a related reason: this page carried NCT07437547 as a live randomized phase 2 of BPC-157, 120 participants planned, and called it the one trial on the register worth watching. The sponsor named on that record has eight studies on ClinicalTrials.gov, two of which describe themselves as specimens in their own summaries, one opening "This fictional study is an example of a ClinicalTrials.gov-style record". All eight share one facility and one pair of contact addresses, on an email domain that does not match the sponsor's name. We cannot show that NCT07437547 is a fabrication and we are not claiming it. We are saying it cannot carry a sentence about what is coming, so the sentence is cut and the paragraph now says what is true: no trial of the blend exists and none is registered.

What we did not do: keep the numbers and attribute them to "a published chart", to "community charts" or to "a chart we read". That reads as sourced while pointing at nothing a reader can open, which is worse than saying less, because it looks like evidence.

What is left is what we can show you: the label the vial carries, the arithmetic that follows from it, the published evidence on each of the four peptides one at a time, and the regulator's own record. Where a question has no answer we can source, this page now says so instead of answering it.

What we hold a citation to before it goes in: the test is set out on the methodology page, along with how a correction to any figure here gets logged.

Last reviewed: 2 August 2026.

1. 1

   Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID 40005999.

2. 2

   Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8. PMID 30915550.

3. 3

   Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID 22074294.

4. 4

   Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. doi:10.1111/j.1749-6632.2010.05490.x. PMID 20536470.

5. 5

   Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346.

6. 6

   Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID 16847171.

7. 7

   U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2), including the "nominated but withdrawn" list. Content current as of 22 April 2026. Accessed 28 July 2026. fda.gov/drugs/human-drug-compounding.

8. 8

   Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424.

9. 9

   Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026 Apr 12. Online ahead of print. doi:10.1007/s40279-026-02437-0. PMID 41966639.

10. 10

    U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: meeting notice, agenda and evaluated uses; FDA Briefing Document; and the FDA presentations delivered on 23 July 2026 for BPC-157, KPV and TB-500. Docket FDA-2025-N-6895. Accessed 28 July 2026. meeting page, briefing document, 23 July presentations.

11. 11

    National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, Msh (11-13), the KPV tripeptide, which is 10 of the 80 milligrams on the KLOW label and the source of the identifiers quoted in the composition section above. Molecular formula C16H30N4O4, molecular weight 342.43, CAS 67727-97-3. Accessed 28 July 2026. pubchem.ncbi.nlm.nih.gov/compound/125672.

12. 12

    Preprint, not peer reviewed. Mendias CL, Awan TM. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org, posted 24 April 2026: 6,441 samples across fourteen compounds, 41.6% to 71.1% failing quality criteria depending on the model applied, measurable endotoxin in 15%. doi:10.20944/preprints202604.1748.v1. Record confirmed through CrossRef on 30 July 2026, HTTP 200, which gives posted, issued and published as 24 April 2026; the publisher page returned HTTP 403 to an automated request. This page carried 27 April until 30 July 2026, which is the date CrossRef records for depositing the DOI, not the date the manuscript went up.

13. 13

    News reporting of the committee vote, not an FDA record. Perrone M. FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr. Associated Press, 23 July 2026. apnews.com. NBC News, 23 July 2026, giving the 8 yes, 6 no, 1 abstention breakdown for BPC-157, KPV and TB-500 and the composition of the yes votes. nbcnews.com. Both retrieved 29 July 2026, HTTP 200. The FDA voting questions are in the meeting's own questions document, HTTP 200 the same day.